Stock News: Action can be seen on Monday in shares of Pharma sector company Zayadas Life Causes included in the BSE 200 index. The company has said that it has received approval for two drugs from the Food and Drug Administration of the United States. According to the company, the annual sales of both these drugs in the US are more than Rs 30 crore. The company informed about this approval on Saturday. In such a situation, the effect of news can be seen in Monday’s business. Pharma company shares closed down nearly 2 percent on Friday.
Find out what the company gave.
The company has stated that Zidas has received a final approval from the USFDA for Ibuprofen and Famotidine Tablet. Both these tablets will be constructed in Zidas Lifesains (SEZ) Ahmedabad. According to the company, the annual sales of both these drugs in the US are $ 3.6 million. According to the company, it has received 415 approvals so far.
How is the stock performance?
On Friday, the company’s shares fell 1.68 percent to close at Rs 885. The stock is currently trading near the lowest level of the year. The annual minimum price of this stock was ₹ 862.2, which was recorded this week. The highest level of this stock is 1324, which was recorded on 9 August. The stock was at Rs 900 a year ago.
